High plasma concentrations of non-esterified fatty acids (NEFAs), transported bound to serum albumin, are associated with type 2 diabetes (T2D). The effects of albumin on platelet function were investigated in vitro. Modifications of albumin, such as those due to glycoxidation, were found in patients with T2D, and the consequences of these modifications on biological mechanisms related to NEFA handling were investigated. Mass spectrometry profiles of albumin from patients with T2D differed from those from healthy controls.
INTRODUCTION
Many epidemiological studies have established an inverse relationship between the level of serum albumin and the risk of death (1;2). After adjustment for usual risk factors, this association was also found to hold not only for liver dysfunction (3) but also for cardiovascular disease and stroke (4) (5) (6) . Albumin is involved in several biological mechanisms, including the regulation of oncotic pressure, and the binding and transport of a number of hydrophobic or amphipathic molecules (mainly non-esterified fatty acids, NEFAs).
In addition, albumin displays potent antioxidant and free radical scavenging activities through the redox cycling of its free thiol (Cys34) (7) and its ability to bind metal ions (2;8;9) . High levels of NEFAs are associated with type 2 diabetes and metabolic syndrome (10;11), and they are known to mediate ventricular arrhythmia and sudden death (10;12) .
Hypoalbuminemia resulting from either very rare familial deficiency or increased clearance in kidney disease has been associated with both abnormally elevated NEFA concentrations in serum and high cardiovascular risk (13) , suggesting a putative role of serum albumin in NEFA metabolism. Low plasma concentrations of albumin are known to have adverse effects, and high levels of glucose and free radicals may impair the biological properties of serum albumin through the formation of harmful adducts (14) . The non-enzymatic covalent attachment of glucose molecules to protein and the subsequent free-radical-mediated oxidation give rise to advanced glycoxidation end (AGE) products of which methylglyoxal (MGO) is considered a key component through the Amadori rearrangement (15) . Several reports indicate that AGE products are able at least in vitro to induce activation of various cells including platelets (16;17) . In addition to classical glycaemic indices, several recent reports indicated that glycated albumin is a relevant and practical biomarker for the progression of diabetic atherosclerosis (18) (19) (20) .
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Although most circulating NEFAs are produced by the adipose tissue during lipolysis, phospholipases also contribute to NEFA production during the platelet activation process.
Blood platelets are not only essential for primary haemostasis, but they also play a central role in the pathophysiology of atherothrombosis. Upon adhesion and activation by various stimuli (such as thrombin, ADP and prostanoids), platelets undergo shape changes, express receptors, aggregate and release their cytosolic granule content (21). Clinical and epidemiological studies provide strong evidence for an association between platelet hyperactivity and atherothrombosis (22). Numerous investigations have reported that risk factors for cardiovascular diseases such as tobacco smoking, hyperlipidemia, hypertension and diabetes are associated with enhanced adhesion, as well as spontaneous and inducible platelet activation (23;24).
Arachidonate can bind to albumin, which can then modulate its conversion into active oxidized metabolites. However, current knowledge concerning the influence of modified versus native albumin on blood platelets, in particular on their ability to release arachidonate metabolites is scarce. In the first part of the present study, we investigated abnormalities in the structure and NEFA-binding property of albumin in plasma of T2D patients as compared to healthy controls. In the second part, we set up an experimental protocol to reproduce in vitro the harmful derivatives of albumin that actually occur in the plasma of T2D patients. Finally, we demonstrated that unmodified albumin can exert a negative regulatory effect on platelet adhesion and aggregation. When glycoxidation of albumin occurs, its fatty acid binding capacity diminishes, and fewer arachidonate molecules are sequestered. Thus, more arachidonate is available for conversion into eicosanoids, which are potent platelet activators.
This newly described mechanism might contribute to the elevated thromboembolic risk in patients with T2D.
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MATERIAL AND METHODS
Subjects
Control subjects were healthy volunteers (n=20) with no history of hyperlipidemia, coronary artery disease or diabetes. Patients (n=20) had type 2 diabetes. The protocol was approved by the local medical ethics committee, and all participants gave written informed consent. The clinical and biological parameters of the subjects are described in Table 1 . For the patients with type 2 diabetes, 7 were received insulin treatment, 11 were treated with sulfamide and 11 with metformin. Five patients received a treatment with a fibrate and 14 were treated with a statin for hyperlipidaemia. One patient was administrated an antiplatelet agent. As stated by creatinine clearance, there was not any patient in a severe chronic renal insufficiency (clearance <30 mL/min) and 3 had a moderate chronic renal insufficiency (clearance between 30 and 60 mL/min).
Blood sampling
Fasting blood samples were collected and specifically handled for each test. Plasma was obtained from citrate-containing glass tubes and separated by centrifugation (15 min, 4°C, 3000xg). Routine biochemistry analyses (plasma lipids, lipoproteins and apolipoproteins)
were performed according to standard protocols (25;26). Plasma albumin concentrations were measured by a standard procedure using bromocresol green with human albumin as the standard (27;28).
Albumin purification and analyses
Blue Sepharose (Pharmacia Fine Chemicals) was used for albumin isolation by gel purification according to previously published procedure (29) . Briefly, the plasma (1.350 mL)
was mixed with the gel (2.5 mL) equilibrated with starting buffer (50 mmol/L Tris/HCl (pH 7.4) and 0.5 mol/l NaCl). After centrifugation (4000xg, 5 min, 4 °C), the supernatant was discarded. The gel was washed three times with starting buffer under the same conditions.
Gel-bound albumin was eluted (0.650 mL) with 50 mmol/l Tris/HCl (pH 7.4) containing 1.5 mol/L NaCl.
Proteomics and MS analysis
Two-dimensional analyses: Native bovine serum and human albumin, MG and Glc-treated albumin, and isolated albumin fractions from controls or type 2 diabetes patients and protein 
Antioxidant status
The antioxidant defence of the subjects was examined using a test based on in vitro freeradical-induced blood haemolysis (27;30). Fasting blood samples were drawn using 10% (v/v) buffered sodium citrate as the anticoagulant. Haemolysis was started by adding 52.4 mmol/L 2,2′-azo-bis(2-amidinopropane) HCl (AAPH) and was assayed by monitoring absorbance at 450 nm (Dynatech MR5000) of diluted blood from the subjects. Results are expressed as 50% of maximal haemolysis time (HT50 in min) and referred to as the susceptibility of blood to free radicals. In humans and other animals in which oxidative stress has been well
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documented, HT50 was shown to be representative of the total defences against free radicals (31) .
Plasma lipid peroxidation was measured as thiobarbituric acid reactive substances (TBARS) in the presence of 2,6-di-tertbutyl-p-cresol (BHT) and expressed as malondialdehyde equivalents as previously described (30) .
Platelet preparation, aggregation and adhesion
As we need a robust tool to test the effects of various albumin preparations on platelet function, we chose to use rat platelets because due to their well-known lower reactivity, they present a much higher reproducibility in terms of activity and signalling compared to those from humans (32) .
Animals
Male white Sprague-Dawley rats (230-250 g) of 7 weeks of age, purchased from Charles River, (L'Arbresle, France) were used as blood donors. They were housed in an air- 
Platelet biochemistry
Platelet labelling and extraction of arachidonate metabolites: Phospholipids of washed rat platelets were labelled as previously described (33) Calcium uptake studies: Calcium uptake by platelets was measured using radiocalcium 45 CaCl 2 (Amersham), following published methods (33;34) . Briefly, after the calcium concentration was adjusted to 0.3 mM, radiocalcium was added to the platelet suspension (5 x 10 8 /ml), 1 min before incubation with thrombin (0.08 IU/ml) and centrifuged (9000 x g, 30 sec) through a layer of separating oil. The platelet pellet was then treated with 0.5 ml 0.5% Triton X-100 and transferred to counting vials with scintillation fluid. The results of the thrombin-induced calcium uptake were expressed as pmoles Ca 2+ per 10 9 platelets and compared with appropriate controls.
Platelet production of reactive oxygen species (ROS):
To measure intraplatelet ROS, we used dichlorofluroscin diacetate (DCFH) in the reduced non-fluorescent form, which is able to Page 9 of 45 Diabetes penetrate platelets as described in previous works (37) . The results were expressed as pmol DCF per 10 7 platelets using a calibration curve constructed with pure DCF.
Modifications of albumin
As the SH group in most commercial BSA and HSA preparations is in the oxidized form ( HSA preparations were used as the starting material for all our studies. Proteins were measured using the bicinchoninic acid technique (Pierce) (39) .
Glycated BSA (G25-BSA) was obtained as previously detailed by Bourdon et al. (14) .
Briefly, BSA was incubated with 25 mM glucose in sterile conditions for 30 days at 37°C under argon. Excess glucose was removed by extensive dialyses against PBS pH 7.4. BSA was also modified with 2 mM methylglyoxal (MGO) for 24h at 37°C. Excess MGO was removed by extensive dialyses against PBS to obtain MGO-modified BSA (MGO-BSA).
Similar modifications were performed with HSA to get G25-HSA and MGO-HSA. 
Measurement of thiol groups:
Fluorescence studies of albumin preparations:
As BSA contains two tryptophan residues (Trp213 and Trp134), and HSA a single tryptophan (Trp214), we were able to evaluate the effects of albumin modifications by monitoring the Page 10 of 45 Diabetes molecular conformation change by assaying its intrinsic fluorescence. Fluorescence measurements of albumin preparations were monitored using a spectrofluorometer (LS50B, Perkin Elmer) at excitation and emission wavelengths of 293 nm and 340 nm, respectively, as in previous studies (14) . Quenching of fluorescence was also measured as previously 
Curve fitting and statistical analyses
Data are expressed as means ± standard deviations (SD) from at least three experiments performed in triplicate. Linear and non-linear curve fitting as well as the statistical comparisons were evaluated using one-way analysis of variance (ANOVA) followed by the Bonferroni post-test performed with Prism software (Graphpad Software Inc., San Diego, CA). Analysis of covariance (ANCOVA) was used to examine the effect of T2D on plasma albumin levels when age was controlled. Statistical analyses were performed with STATA software, version 11 (Statacorp, Texas, USA).
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Biostatistics for proteomics: Thirty spectra were available from the MALDI-TOF/TOF analysis, but 6 of these did not meet biological criteria and were removed from the analysis.
The following steps were taken to process the raw data: de-noising, baseline subtraction and normalization. Peaks were identified and quantified by their intensities. Statistical analysis was thus performed on 24 spectra (8 healthy and 16 diabetic spectra respectively representing healthy and diabetic patients) for 231 variables. Data were pre-processed and analysed using R software (44) . Principal components analysis (PCA) was implemented to visualize the principal sources of variability in the data. (45) was thus implemented on the data to select peaks which mostly contribute to discriminate between both groups. This method is derived from PLS (46) . The aim of the SPLS is to reduce the dimensionality of the dataset by finding new components which maximize the discrimination between diagnostic groups.
SPLS simultaneously makes it possible to select variables that mostly contribute to the discrimination, thus facilitating the biological interpretation; 20 peaks were thereby selected by SPLS as those separating at best samples from Controls and samples from patients with diabetes. It was shown that these 20 peaks were sufficient to optimize predictions.
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RESULTS
Patients with T2D display dysfunctional albumin Table 1 shows the clinical and lipid parameters of 20 patients with T2D and 20 matched control subjects. Fasting glycaemia was significantly higher in T2D with a mean HbA1C value of 9.3% as compared with values <6% in control plasma. Triglyceridaemia, plasma NEFAs, age, and BMI were significantly higher in T2D patients than in controls (P<0.01, P<0.05, P<0.001, and P<0.01, respectively). Although total cholesterol and LDLcholesterol did not differ significantly between the two groups, HDL-cholesterol levels were significantly lower in T2D patients (P<0.01). Plasma fibrinogen levels were higher (+12%)
and albumin values were lower (-18%) in T2D patients than in controls with 3-fold higher Glc-HSA in the former group (Table 1) . This could not be ascribable to an impairment of the renal status as creatinine values were normal (92.3±29.9 µmol/L) as well as the MDRD (Modification of the Diet in Renal Disease) marker (64.2±26.8 mL/min). Glycated LDL, TBARS and OxLDL levels were significantly higher in T2D than in controls (P< 0.05 in all cases). Total free radical defence was measured on whole blood samples, and the HT50 parameter (i.e. the 50% maximal haemolysis time) was found to be significantly shorter in T2D than in controls (P<0.01). These results are in favour of a general impairment of the redox status in T2D patients. This is in line with the reduced plasma thiol level in T2D patients compared with controls (P<0.01 - Table 1 ).
Albumin was isolated from the plasma of controls and T2D patients. HSA fractions obtained for 6 controls and 6 T2D patients were subjected to two-dimensional SDS-PAGE and the corresponding Coomassie-stained spots were analysed by proteomics. After digestion with trypsin and extraction from gel pieces, peptide fragments were identified and quantitated following MALDI-TOF/TOF analysis. Principal component analysis (PCA) enabled to show (45) aimed to make a regression on components retaining only peaks the most contributing to discrimination. This method was implemented on the data and 20 peaks were sufficient to separate the two groups (Fig. 1A) . A detailed comparative analysis of the most important peaks of trypsin-treated HSA highlighted by SPLS, indicated that intensities differed between the two groups, suggesting differently modified residues (especially Lys) (Fig. S2) . From these data, it can be concluded that albumin fractions isolated from the plasma of Controls and T2D patients have different structural characteristics.
HSA fractions were also specifically assayed for their thiol content and antioxidant properties using a free radical-induced haemolysis test. We found a significantly lower level of total plasma thiols (-28%, P<0.01, especially with a lower level of albumin-associated free thiols, -29%, P<0.01), as well as shorter HT50 times (-30%; P<0.01) in T2D patients than in controls (Table 1) . These data illustrate the reduced antioxidant capacity of T2D albumin as compared with control albumin. The fatty acid binding capacity of albumin from controls and T2D patients was evaluated through incubations with increasing concentrations of oleic acid.
As shown in Figure 1B , the maximum fatty acid binding capacity (Bmax) of isolated albumin was significantly lower in T2D than in controls (-32%, P<0.001). The half-saturation value (apparent Sat50) of albumin was reached with a lower concentration of oleic acid for T2D patients than for control subjects (4.61±1.05 vs. 6.60±1.08 µmol/L, respectively; P<0.001).
Taken together, these data come in support of reduced saturation of T2D albumin in the presence of oleic acid, and suggest that the capacity of T2D albumin to bind unesterified fatty acids is blunted. This finding comes in addition to the lower albumin levels in T2D patients than in controls (Table 1) .
Albumin glycated in vitro mimics the main features of albumin from T2D patients
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Native human albumin (N-HSA) was treated in vitro with either 25 mM glucose (G25-HSA) or 2 mM MGO (MGO-HSA). The experimental conditions were identical to those previously described and specifically set up to reproduce in vivo modifications resulting from hyperglycaemia (14) . As expected from earlier data for glycation (14) and as illustrated in patients (Diab-Alb) were found to behave similarly to MGO-HSA and G25-HSA, while, in contrast, albumin from control subjects did not differ from native albumin.
We further aimed to characterize the structural modifications induced in albumin under our experimental conditions, as well as the putative changes in the properties of albumin. By using DTNB, we found that fewer thiol groups were available in G25-BSA and MGO-BSA than in N-BSA (-59 and -31%, respectively; P<0.01 - Table 2 ). In addition, there were significantly fewer free Lys-NH2 groups in G25-Alb and MGO-Alb than in N-BSA (-29 and -33%, respectively; P<0.01 - Table 2 ). As revealed by polyacrylamide gel electrophoresis, our conditions did not result in extensive damage to the protein, with no detectable fragmentation or aggregation (data not shown). ANSA fluorescence data indicated that alterations in albumin conformation led to major decreases in the accessibility of hydrophobic domains. These observations were similar for MGO-and G25-BSA (Fig. 3A) .
As it is well known that albumin binds and transports NEFAs, our results concerning ANSA binding prompted us to specifically investigate the interactions of fatty acids with regard to albumin modifications. After the incubation of distinct fatty acid-free albumin preparations with increasing amounts of oleic acid, maximal absorbance was measured in the 280-300 nm range according to previous works (43) . Under our experimental conditions, we found a gradual increase in the absorbance at about 292 nm, which could be fitted according to a binding hyperbole (Fig. 3B) . The apparent Kd value calculated with N-Alb was 1.6±0.4
µM whereas it was up to 4.5 times higher with modified albumin (P<0.001 - Fig. 3B ). These results indicate that, because of the modifications, albumin lost part of its affinity for NEFAs since oleate binding is considered as a good representative of other fatty acids (47) . Based on curves obtained in Fig. 3B , and as compared to N-Alb, we found that albumin modified with G25 and MGO had a significantly decreased maximal binding capacity for oleate.
Modification of BSA and release of active arachidonate derivatives
Arachidonate-labelled platelets were used to monitor the effects of the arachidonate pathway on thrombin stimulation in the presence of increasing concentrations of native or modified BSA. We chose to use rat platelets because of their known easy handling that confer a better reproducibility than human platelets, especially for long term incubation (32;33;48).
Under our experimental conditions, most of the labelling material was recovered in the platelet phospholipids with no difference in the relative distribution of the phospholipid fractions whether albumin was added or not (not shown). The thrombin-induced mobilisation of radiolabelled AA pre-incorporated into phospholipids and the subsequent formation of labelled cyclooxygenase (COX) and lipoxygenase (LOX) products were measured. After only 2 minutes of stimulation, labelled AA was released from the phospholipids, and the main metabolites (i.e. the stable derivatives of thromboxane A 2 , thromboxane B 2 (TXB 2 ), 12-hydroxy-heptadecanoic acid (12-HHT) and 12-hydroxy-eicosatetraenoic acid (12-HETE))
were detected in platelet extracts. The production of active metabolites of the COX pathway
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(HHT and TxB2) and of the LOX pathway (HETE) was significantly higher with modified albumin (G25-BSA and MGO-BSA) than with native BSA (Figure 4 ).
These observations suggest that platelet-released arachidonate is sequestered by native albumin, and thus becomes less available for conversion into active metabolites by cycloxygenase (COX) and lipoxygenase (LOX) enzymes. In contrast, with glycoxidized albumin, higher amounts of phospholipid-derived arachidonate are available for conversion into oxidized derivatives, and concordant observations were made with G25-and MGO-BSA.
Albumin modification and platelet activity
First, the appropriate conditions to investigate the effect of albumin on platelet aggregation were set up. The results illustrated in Fig. 5A clearly indicate that increased concentrations of N-BSA led to an increased inhibitory effect of albumin on platelet aggregation (as induced by various agonists such as thrombin, ADP, calcium ionophore A23187 and arachidonate). In addition, the spontaneous adhesion of platelets to the microplates was found to be gradually inhibited when the microplates were coated with increasing amounts of N-BSA (Fig. 5B) . In contrast, and in agreement with earlier observations (35) , coating with collagen resulted in platelet adhesion as uncoated wells ( Figure 5B). To investigate further the inhibitory properties of albumin on platelet signalling, we also analysed TxB2 release by means of an ELISA and calcium fluxes in the presence of radiocalcium. Thrombin-induced TxB2 was significantly reduced and in a concentrationdependent manner in the presence of increasing concentrations of N-BSA (Fig. 5C1) . The basal calcium uptake, measured without thrombin, was not different whether N-BSA was added or not (data not shown). In contrast, the thrombin-induced calcium influx was significantly reduced with increasing concentrations of N-BSA (Fig. 5C2) . To analyse whether N-BSA influenced platelet oxidative metabolism, platelets were probed with DCFH.
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N-BSA significantly decreased arachidonate-mediated DCF production in a dose-dependent way (Fig. 5C3) .
Again, albumin was modified by incubation with 25 mM glucose (G25-BSA) and MGO (MGO-BSA), and preparations were tested for their effects on platelet function in comparison with N-BSA at identical final concentrations (2 mg/mL). The results for thrombin-induced platelet aggregation and platelet adhesion are shown in Fig. 6 . We found that G25-BSA and MGO-BSA significantly lost their inhibitory capacity on platelet aggregation as compared to N-BSA (Fig. 6A) . Similarly, the inhibitory effect on platelet adhesion was greatly impaired when wells were coated with modified albumin (Fig. 6B ). In addition, platelet signaling (Fig. 6C, 6D ) and ROS production ( Fig. 6E ) stimulated with thrombin were also impaired following incubation with modified albumin preparations as shown by calcium uptake and DCF level.
Finally, platelets were incubated with albumin fractions isolated from control subjects and patients with T2D and they were stimulated with thrombin. As for native HSA which was used in control samples, albumin isolated from healthy control subjects was able to markedly inhibit the thrombin-induced aggregation of platelets (Fig. 6F) . As compared to albumin isolated from healthy control subjects, albumin from patients with TD2 diabetes displayed an impaired capacity to block platelet aggregation (44.0 % in TD2 patients versus 80.9 % in healthy controls). These results are in line with observations made above with modified BSA.
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DISCUSSION
In the present work, albumin abnormalities resulting from glycation and glycoxidation were characterized. They were found to produce significant impairment in the binding capacity of non-esterified fatty acids (NEFAs) as found in patients with type 2 diabetes (T2D), thus contributing significantly to platelet hyperactivity in this population. A high level of circulating NEFAs is predictive of sudden death, stroke and ischemic heart disease as reported by a large number of population studies (10;58;59). The numerous deleterious effects such as cardiac arrhythmia, and proinflammatory and prothrombotic states have been the subject of intense research, which has shown that some of the deleterious effects could be directly attributed to elevated plasma NEFAs (12;60). However, though the effects of high levels of total plasma NEFAs have been studied (10;11;61), the putative deterioration in the NEFA binding capacity of albumin was not addressed in a systematic way. In previous studies, it was reported that oxidative stress and glycation caused conformational changes in albumin structure (14;29;62) 
